Abstract
It has been hypothesized that efficacy of spironolactone (spirono) in heart failure (HF) with reduced left ventricular ejection fraction (LVEF) may differ by race with less clinical benefit in African-Americans. There is no clinical data regarding other races. From 2002 to 2012, all consecutive
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.